Moderna, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Moderna, Inc. (MRNA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 8.91 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-02-20
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-12-31 was 200.00K shares, a 11.97% decline year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-09-30 was 150.00K shares, a 79.47% decline year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-06-30 was 260.00K shares, a 47.33% decline year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-03-31 was 870.00K shares, a 75.73% decline year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 8.91M shares, a 166.77% increase from fiscal 2024.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.34M shares, a 23.39% decline from fiscal 2023.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 4.36M shares, a 62.08% increase from fiscal 2022.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.69M shares, a 81.76% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 8.91M shares 10-K · filed 2026-02-20 | |||
| 2024-12-31 | 3.34M shares 10-K · filed 2025-02-21 | |||
| 2023-12-31 | 4.36M shares 10-K · filed 2024-02-23 | |||
| 2022-12-31 | 2.69M shares 10-K · filed 2023-02-24 | |||
| 2021-12-31 | 200.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | 350.00K shares derived: sum of 2 quarters · filed 2022-02-25 | 610.00K shares derived: sum of 3 quarters · filed 2022-02-25 | 1.48M shares 10-K · filed 2022-02-25 |
| 2021-09-30 | 150.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 410.00K shares derived: sum of 2 quarters · filed 2021-11-04 | 1.28M shares 10-Q · filed 2021-11-04 | 1.51M shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 260.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 1.13M shares 10-Q · filed 2021-08-05 | 1.36M shares derived: sum of 3 quarters · filed 2021-08-05 | 2.09M shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 870.00K shares 10-Q · filed 2021-05-06 | 1.10M shares derived: sum of 2 quarters · filed 2021-05-06 | 1.83M shares derived: sum of 3 quarters · filed 2021-05-06 | 2.32M shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 227.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | 957.78K shares derived: sum of 2 quarters · filed 2021-02-26 | 1.45M shares derived: sum of 3 quarters · filed 2021-02-26 | 5.04M shares 10-K · filed 2021-02-26 |
| 2020-09-30 | 730.59K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | 1.22M shares derived: sum of 2 quarters · filed 2020-10-30 | 4.81M shares 10-Q · filed 2020-10-30 | 5.62M shares derived: sum of 4 quarters · filed 2020-10-30 |
| 2020-06-30 | 493.67K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 4.08M shares 10-Q · filed 2020-08-06 | 4.89M shares derived: sum of 3 quarters · filed 2020-08-06 | 5.15M shares derived: sum of 4 quarters · filed 2020-08-06 |
| 2020-03-31 | 3.59M shares 10-Q · filed 2020-05-07 | 4.40M shares derived: sum of 2 quarters · filed 2020-05-07 | 4.66M shares derived: sum of 3 quarters · filed 2020-05-07 | 5.50M shares derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | 811.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | 1.07M shares derived: sum of 2 quarters · filed 2020-02-27 | 1.91M shares derived: sum of 3 quarters · filed 2020-02-27 | 7.35M shares 10-K · filed 2020-02-27 |
| 2019-09-30 | 262.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | 1.10M shares derived: sum of 2 quarters · filed 2019-11-06 | 6.54M shares 10-Q · filed 2019-11-06 | |
| 2019-06-30 | 837.68K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | 6.28M shares 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | 5.44M shares 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | 19.22M shares 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |